Prediction of cytogenetic abnormalities with gene expression profiles

Blood

Volumn 119, Issue 21, 2012, Pages

  Zhou, Yiming ^a   Zhang, Qing ^a,c   Stephens, Owen ^a   Heuck, Christoph J ^a   Tian, Erming ^a   Sawyer, Jeffrey R ^a   Cartron Mizeracki, Marie Astrid ^a   Qu, Pingping ^b   Keller, Jason ^a   Epstein, Joshua ^a   Barlogie, Bart ^a   Shaughnessy, John D ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; RNA;

ARTICLE; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CYTOGENETICS; DIAGNOSTIC ACCURACY; DNA ISOLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN TISSUE; KARYOTYPE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; RNA PURIFICATION;

EID: 84861488903     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-388702     Document Type: Article

References (16)

1. Barlogie B, Epstein J, Sanderson R, Anaissie E, Walker R, Tricot G. Plasma cell myeloma. In: Lichtman MA, Kaushansky K, Kipps TJ, Seligsohn U, Prchal J, eds. Williams Hematology (7th Ed). New York, NY: McGraw-Hill; 2005:1501- 1533.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-187. (Pubitemid 37328787)
3. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101(1):189-194. (Pubitemid 28197793)
4. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005; 23(26):6339-6344. (Pubitemid 46218844)
5. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99(5):1745-1757. (Pubitemid 34533050)
6. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96(4):1505-1511. (Pubitemid 30658483)
7. Sawyer JR,Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82(1): 41-49.
8. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-2028. (Pubitemid 44395016)
9. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284. (Pubitemid 46425864)
10. Zhan F, Barlogie B, Arzoumanian V, et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692-1700. (Pubitemid 46239604)
11. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30(4): e15.
12. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23(6):657- 663.
13. Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics. 2000;16(5):412-424. (Pubitemid 30487963)
14. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005; 105(1):358-360. (Pubitemid 40053104)
15. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-948.
16. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.